Biological causes of immunogenic cancer cell death (ICD) and anti-tumor therapy; Combination of Oncolytic virus-based immunotherapy and CAR T-cell therapy for ICD induction
Abstract Chimeric antigen receptor (CAR) T-cell therapy is a promising and rapidly expanding therapeutic option for a wide range of human malignancies. Despite the ongoing progress of CAR T-cell therapy in hematologic malignancies, the application of this therapeutic strategy in solid tumors has enc...
Guardat en:
Autors principals: | Amirhossein Mardi, Anastasia V. Shirokova, Rebar N. Mohammed, Ali Keshavarz, Angelina Olegovna Zekiy, Lakshmi Thangavelu, Talar Ahmad Merza Mohammad, Faroogh Marofi, Navid Shomali, Amir Zamani, Morteza Akbari |
---|---|
Format: | Revisão |
Idioma: | anglès |
Publicat: |
2022
|
Accés en línia: | https://doi.org/10.1186/s12935-022-02585-z https://cancerci.biomedcentral.com/track/pdf/10.1186/s12935-022-02585-z |
Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|
Ítems similars
-
Biological causes of immunogenic cancer cell death (ICD) and anti-tumor therapy; Combination of Oncolytic virus-based immunotherapy and CAR T-cell therapy for ICD induction
per: Mardi, Amirhossein, et al.
Publicat: (2022) -
Mesenchymal stem/stromal cells as a valuable source for the treatment of immune-mediated disorders
per: Markov, Alexander, et al.
Publicat: (2021) -
Mesenchymal stem/stromal cells as a valuable source for the treatment of immune-mediated disorders
per: Alexander Markov, et al.
Publicat: (2021) -
Renaissance of armored immune effector cells, CAR-NK cells, brings the higher hope for successful cancer therapy
per: Marofi, Faroogh, et al.
Publicat: (2021) -
Renaissance of armored immune effector cells, CAR-NK cells, brings the higher hope for successful cancer therapy
per: Faroogh Marofi, et al.
Publicat: (2021)